Table 1. Clinical and demographic characteristics of patients initiated on RR-TB treatment in the SOC-cohort (January 2010—July 2013) versus the SAT-cohort (January 2012—December 2014).
| Patients Started RR-TB Treatment | SOC-cohort | SAT-cohort |
P-value |
|---|---|---|---|
| N = 160 | N = 244 | ||
| n (%) | n (%) | ||
| Sex | |||
| Male | 94 (58.8) | 129 (52.9) | |
| Female | 66 (41.2) | 115 (47.1) | 0.25 |
| Median Age at diagnosis (years) (IQR) | 33.9 (27.2–41.9) | 32.7 (27.2–40.6) | 0.38 |
| TB Treatment History | |||
| No TB treatment history | 38 (23.7) | 98 (40.2) | |
| Previous treatment with 1st line drugs | 103 (64.4) | 113 (46.3) | |
| Previous treatment with 2nd line drugs | 19 (11.9) | 33 (13.5) | <0.01 |
| RR-TB Regimen | |||
| Standard regimen* | 142 (88.7) | 217 (88.9) | |
| Second-line resistance (modified regimen) | 18 (11.3) | 27 (11.1) | 0.95 |
| Disease Site | |||
| PTB | 149 (93.1) | 220 (90.2) | |
| EPTB only | 8 (5.0) | 22 (9.0) | |
| Unknown | 3 (1.9) | 2 (0.8) | 0.22 |
| HIV-infected | 112 (70.0) | 180 (73.8) | 0.41 |
| Median Baseline CD4 count cells/mm3 among HIV-infected (IQR) | 108 (46.5–241.5) | 159 (47–346)** | 0.28 |
| On ART at RR-TB diagnosis | 45/112 (40.2) | 81/180 (45.0) | 0.42 |
| Median months on ART (IQR) | 10.5 (1.8–27.2) | 12.0 (2.1–43.2) | 0.26 |
*Standard Regimen = pyrazinamide/ethionamide/high dose isoniazid/kanamycin/moxifloxacin/
ethambutol/terizidone
**9 patients missing baseline CD4 count
RR-TB, rifampicin-resistant tuberculosis; SOC, standard of care; SAT, self-administered treatment; IQR, interquartile range; TB, tuberculosis; PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; ART, anti-retroviral therapy.